ONKT101 / Avectas, ONK Therap - LARVOL DELTA

Realizing Innate Potential: CAR-NK Cell Therapies for Acute Myeloid Leukemia. (PubMed, Cancers (Basel)) - "Finally, we consider the broader landscape of competing immunotherapeutic approaches to AML treatment. In doing so we evaluate the innate potential, status and remaining barriers for CAR-NK based AML immunotherapy."

Journal • Review • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • CD19

ONK Therapeutics Announces Three Exclusive Option License Agreements, Which Extend and Strengthen its Dual-Targeted NK Cell Therapy Pipeline (Businesswire) - "Three new exclusive option license agreements expand the depth and breadth of ONK’s pre-clinical pipeline; A humanized scFv targeting CLEC12A licensed from Cellerant Therapeutics, creates a fourth pre-clinical program, ONKT104, for the treatment of acute myeloid leukemia (AML); A humanized scFv targeting a novel tumor-specific MUC1 glycopeptide epitopelicensed from Glycotope GmbH, strengthens pre-clinical program ONKT103, for solid tumors; A CCR7 homing receptor licensed from the National Institute of Health (NIH), for use in the pre-clinical ONKT101 program, for relapsed/refractory B cell malignancies."

Licensing / partnership • Acute Myelogenous Leukemia • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Oncology • Solid Tumor